While time to tumor endpoint (2 cm3) was unaffected by CD44 KO in vivo, we found that Hs578T cells took a significantly longer amount of time to form palpable tumors (Figure 5A), consistent with delayed onset noted in the overall survival based on tumor burden (Figure S4B). The gene discussed is CD44; the disease is neoplasm.